Bengaluru: AstraZeneca has cut about 600 jobs from its respiratory and immunology commercial teams in the US as part of its three-year cost-savings initiative, Bloomberg News reported on Friday, citing people familiar with the matter.

The cuts follow the UK-based drugmaker's late-October announcement that it planned to save about $1.5 billion annually and reinvest in its drug pipeline.

Some employees affected by the restructuring are expected to be reassigned within the company, Bloomberg reported.

The reductions come as AstraZeneca CEO Pascal Soriot seeks to reassure investors that the company can meet its target of $80 billion in annual revenue by 2030, while drugmakers more broadly face growing scrutiny over the strength of their pipelines.

AstraZeneca's immunology and respiratory portfolio accounted for 16% of its third-quarter revenue at $2.5 billion. AstraZeneca declined to comment on the report.

Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .